Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 8/20 | 0.89 |
| ▸ | PGR | P06401 | 4/20 | 0.76 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.76 |
| ▸ | HIF1A | Q16665 | 8/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.68 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | SHBG | P04278 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.68 |
| ▸ | AR | P10275 | 3/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14935799 | 0.94 | NR3C2 (1.00) | NR3C2PGRNR3C1HIF1AKMT2A | |
| SCHEMBL14935798 | 0.94 | NR3C2 (1.00) | NR3C2PGRNR3C1HIF1AKMT2A | |
| SCHEMBL17977250 | 0.92 | NR3C2 (0.87) | NR3C2PGRNR3C1HIF1AKMT2A | |
| SCHEMBL10597293 | 0.92 | NR3C2 (0.86) | NR3C2PGRNR3C1HIF1AKMT2A | |
| SCHEMBL11293782 | 0.91 | NR3C2 (0.84) | NR3C2PGRNR3C1HIF1AKMT2A | |
| SCHEMBL28399203 | 0.90 | NR3C2 (0.83) | NR3C2PGRNR3C1HIF1AKMT2A | |
| SCHEMBL82865 | 0.90 | NR3C2 (0.83) | NR3C2PGRNR3C1HIF1AKMT2A | |
| SCHEMBL17977247 | 0.90 | NR3C2 (0.83) | NR3C2PGRNR3C1HIF1AKMT2A | |
| SCHEMBL321463 | 0.90 | NR3C2 (0.84) | NR3C2PGRNR3C1HIF1AKMT2A | |
| SCHEMBL3049344 | 0.90 | NR3C2 (0.84) | NR3C2PGRNR3C1HIF1AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107108613-B | Bromodomain inhibitors and uses thereof | 基因泰克公司 | 2020-02-25 | — | — | CN | disclosed |
| EP-1588703-B1 | FATIGUE REDUCING AGENT | KANEKA CORP (JP) | 2016-04-20 | — | — | EP | disclosed |
| US-8946303-B2 | Fatigue reducing agent | KANEKA CORPORATION (JP) | 2015-02-03 | — | — | US | disclosed |
| EP-1481969-B1 | PIPERIDINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2011-01-19 | — | — | EP | disclosed |
| US-7425567-B2 | Piperidine derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-7378428-B2 | Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-27 | — | — | US | disclosed |
| US-20080064731-A1 | REMEDY FOR CHRONIC DISEASE | ONO PHARMACEUTICAL CO.,LTD. | 2008-03-13 | — | — | US | disclosed |
| US-7300917-B2 | Remedy for chronic disease | ONO PHARMACEUTICALS CO., LTD. (JP) | 2007-11-27 | — | — | US | disclosed |
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| US-20060165672-A1 | Fatigue reducing agent | KANEKA CORPORATION | 2006-07-27 | — | — | US | disclosed |
| US-20060135577-A1 | Remedy for chronic disease | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
| EP-1588703-A1 | FATIGUE REDUCING AGENT | KANEKA CORPORATION (JP) | 2005-10-26 | — | — | EP | disclosed |
| US-20050222138-A1 | Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
| EP-1550461-A1 | REMEDY FOR CHRONIC DISEASE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-06 | — | — | EP | disclosed |
| US-20050080107-A1 | Piperidine derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-04-14 | — | — | US | disclosed |
| EP-1481969-A1 | PIPERIDINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064731-A1 | REMEDY FOR CHRONIC DISEASE | EDNRA, EDNRB, LPAR2 | NR3C2 55/4885PGR 1452/4885NR3C1 159/4885 |
| US-20050080107-A1 | Piperidine derivative compounds and drugs containing the compounds as the active ingredient | PDCD4, PDE4B, IRAK4 | NR3C2 3289/4885PGR 820/4885NR3C1 914/4885 |
| US-20060165672-A1 | Fatigue reducing agent | CPT1B, RECQL, NDUFB5 | NR3C2 4164/4885PGR 4543/4885NR3C1 3375/4885 |
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | NR3C2 187/4885PGR 450/4885NR3C1 34/4885 |
| US-20060135577-A1 | Remedy for chronic disease | EDNRA, EDNRB, LPAR2 | NR3C2 55/4885PGR 1452/4885NR3C1 159/4885 |
| US-20050222138-A1 | Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient | PARK7, MMP8, CDK7 | NR3C2 94/4885PGR 589/4885NR3C1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.